At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 192 enrolled
Drug / intervention
Nemolizumab +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Single-Dose, Open-Label, Parallel-Group Study in Healthy Volunteers to Assess the Relative Bioavailability of a Subcutaneous Dose of Nemolizumab When Administered With Auto-Injector Compared to Dual-Chamber Syringe
In Brief
A Phase 1 clinical trial evaluating Nemolizumab for Healthy Volunteers. Completed, enrolled 192 participants across 2 sites.
Detailed Summary
This study was to compare the rate and extent of absorption of a single dose of nemolizumab administered with auto-injectors \[AI\] (test) versus dual-chamber syringes \[DCS\] (reference) under controlled conditions in healthy adult subjects.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy Volunteers
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
2023202420252026
First PostedJun 2022
Enrollment StartAug 2022
Primary CompletionNov 2022
Study CompletionDec 2022
TodayJul 2026
First PostedJun 6, 2022
Enrollment StartAug 11, 2022
Primary CompletionNov 11, 2022
Study CompletionDec 8, 2022
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 4.1 years ago
Interventions
Nemolizumabdrug
Nemolizumab with Auto-Injector (AI).
Nemolizumabdrug
Nemolizumab with Dual-Chamber Syringe (DCS).